Phage Therapy as a Protective Tool Against Pathogenic Bacteria: How Far We Are?

Author:

Chakrabarti Alok Kumar1,Singh Kushagri1,Biswas Asim2,Dutta Shanta1

Affiliation:

1. Division of Virology, Vibrio Phage Reference Laboratory, National Institute of Cholera and Enteric Diseases, Kolkata, West Bengal, India

2. School of Veterinary Medicine, Pathobiological Sciences, Influenza Research Institute (IRI), University of Wisconsin-Madison, Madison, Wisconsin

Abstract

Abstract: Bacterial infections continue to jeopardize human and animal health, impacting millions of lives by causing significant deaths every year. The use of antibiotics remains the primary choice of therapy and has only been partly successful in reducing the disease burden due to the evolving nature of resistant microbes. Widespread and inappropriate use of antibiotics resulted in the development of antibiotic-resistant microbial species provoking substantial economic burdens. The most promising way to resolve the issue of antibiotic resistance is the use of bacterial viruses called bacteriophages to treat microbial infections. Earlier reports on experimental bacteriophage therapy showed successful patient outcomes, and many clinical trials of such clinical bacteriophages have already been investigated in many western countries. In this review, we are focusing on the advantages as well as drawbacks of bacteriophage therapy to use it as an alternative to antibiotics for microbial infections, together with its current success status. There is also a need to extensively study the past, present, and future outlook of phage therapy in comparison to presently available antimicrobial agents and especially immunological response by the host after phage administration. Our aim is to highlight the fast-promoting field of bacteriophage therapy and provocations that lie ahead as the world is gradually moving aside from complete dependence on antimicrobial agents.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmaceutical Science,Biotechnology

Reference123 articles.

1. D’Herelle F.; Malone R.H.; A preliminary report of work carried out by the cholera bacteriophage enquiry. Ind Med Gaz 1927,62(11),614-616

2. Aminov R.; Caplin J.; Chanishvili N.; Coffey A.; Cooper I.; De Vos D.; Doškař J.; Friman, V.P.; Kurtböke,İ.; Pantucek, R.; Pirnay, J.P.; Resch, G.; Rohde, C.; Sybesma, W.; Wittmann, J. Application of bacteriophages. Microbiol Aust 2017,38(2),63-66

3. Fleming A.; On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 1929,10(3),226

4. Summers W.C.; The strange history of phage therapy. Bacteriophage 2012,2(2),130-133

5. Tang S.S.; Biswas S.K.; Tan W.S.; Saha A.K.; Leo B.F.; Efficacy and potential of phage therapy against multidrug resistant Shigella spp. PeerJ 2019,7

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3